Statement of significance: Dysregulated glycemic control increases cancer risk and impairs disease prognosis. This study identifies several novel mechanisms underlying impaired glycemic control in cancer.
Introduction
Epidemiological and clinical studies show an association between several types of cancers and poor glycemic control in humans. For example, one-third of cancer patients are glucose intolerant (1), which is of clinical relevance as cancer patients with type 2 diabetes have increased mortality rates (2) . Furthermore, recent studies have suggested that insulin resistance could be an underlying cause of cancer-associated loss of muscle and fat mass, called cancer cachexia (3) (4) (5) . Cachexia occurs in 60-80% of cancer patients and is associated with poor prognosis (6) . Despite the link between cancer, cancer cachexia and insulin resistance, the tissue-specific mechanistic and molecular cause(s) of insulin resistance in cancer is largely unexplored.
Skeletal muscle and adipose tissue are essential for maintaining whole-body glucose homeostasis by taking up the majority of glucose in response to insulin in healthy humans (7) . Insulin promotes glucose disposal in skeletal muscle and adipose tissue by increasing microvascular perfusion as well as mediating glucose transport across the cell membrane (8) (9) (10) . Previous non-cancer studies found decreased insulin-induced muscle microvascular perfusion and glucose transport in insulin-resistant conditions, like obesity and type 2 diabetes (11, 12) . Reduced muscle glucose uptake has been reported in patients with cancer (13, 14) , however whether insulin resistance in cancer is associated with molecular malfunctions in skeletal muscle and adipose tissue, and whether impaired muscle microvascular perfusion is a potential cause of reduced insulin-stimulated glucose uptake have to our knowledge, not previously been determined.
Fatty acid oxidation and/or adipose tissue lipolysis are increased in many cancers (15) (16) (17) .
Interestingly, excessive fatty acids in the circulation can cause insulin resistance and have been suggested as a cause of insulin resistance in obesity and type 2 diabetes (18) (19) (20) . Moreover, some literature suggests that excessive fatty acid turnover is a leading cause of cancer cachexia because blockade of fatty acid oxidation or suppression of lipolysis in adipose tissue prevents cachexia in tumor-bearing mice (21) (22) (23) . Given the link between insulin resistance and cachexia (3) (4) (5) , altered fatty acid turnover could be involved in the poor glycemic regulation observed in many cancers.
However, a role for altered fatty acid turnover in cancer-associated impaired glycemic regulation is unexplored.
The aim of the present investigation was to elucidate tissue-specific contributions and molecular mechanisms underlying impaired glycemic regulation in cancer and we hypothesized that altered fatty acid turnover would be involved in cancer-associated insulin resistance.
Here, we found that cancer caused significant whole-body insulin resistance and glucose intolerance that was restored by blockage of adipose tissue lipolysis or whole-body fatty acid oxidation. Insulin resistance in tumor-bearing mice was associated with i) impaired glucose uptake in adipose tissue and skeletal muscle despite augmented muscle insulin signaling, ii) abrogated muscle microvascular perfusion in response to insulin, and iii) increased basal hepatic glucose production.
Methods
Cell culture. Lewis lung carcinoma cells (LLC, ATCC® CRL1642™) were cultured in DMEM, high glucose (Gibco #41966-029,USA) supplemented with 10% fetal bovine serum (FBS, Sigma-Aldrich #F0804, USA), 1% penicillin-streptomycin (ThermoFisher Scientific #15140122, USA) (5% CO2, 37°C). Prior to inoculation into mice, LLC cells were trypsinized and washed twice with PBS.
LLC cells were suspended in PBS with a final concentration of 2.5 * 10 6 cells/ml. Animals. Female C57BL/6J (Taconic, Lille Skensved, DK) mice were acclimatized one week following arrival to the facility. Mice were group-housed at ambient temperature (21-23°C) with nesting materials and kept on a 12 h:12 h light-dark cycle with access to a standard rodent chow diet (Altromin no. 1324, Brogaarden, DK) and water ad libitum. At the age of 12-14 weeks, mice were randomly assigned into control (Control) or LLC tumor-bearing (LLC) groups and subcutaneously inoculated with 100 µl PBS with or without 2.5 * 10 5 LLC cells into the right flank.
Control and LLC tumor-bearing mice were sacrificed at two time points: 15 days (LLC Day 15) and [21] [22] [23] [24] [25] [26] [27] Etomoxir and nicotinic acid administration. As mice housed at ambient temperature are mildly cold stressed and preferentially metabolize more lipids than carbohydrate (25) , we reasoned that inhibiting fat metabolism might cause undue metabolic stress at ambient temperature and therefore we performed this part of the experiment at thermoneutrality (30°C). After 3 weeks of acclimatization and mimicking intraperitoneal (i.p) injection every other day using empty syringes, LLC inoculation was performed as described above. Half of the tumor-bearing mice were i.p.
injected daily with 5 mg/kg body weight ethyl-2-[6-(4-chlorophenoxy)hexyl]-oxirane-2-carboxylate (etomoxir) (Sigma-Aldrich, US), an inhibitor of fatty acid oxidation, dissolved in 5% (2-Hydroxypropyl)-β-cyclodextrin solution from day 8 following tumor inoculation (LLC-Eto). The other half of the tumor-bearing mice (LLC) and non-tumor-bearing control mice (Control) were i.p. injected with 5% (2-Hydroxypropyl)-β-cyclodextrin solution. Mice were sacrificed 18 days following tumor inoculation.
The nicotinic acid-administrated mice (LLC-Nico), inhibitor of adipose tissue lipolysis, were maintained and treated similar to etomoxir-administrated mice, with the exception that 50 mg/kg body weight of nicotinic acid (Sigma-Aldrich, USA) dissolved in 5% (2-Hydroxypropyl)-βcyclodextrin solution was i.p. injected daily from day 8 following tumor inoculation. Mice were sacrificed 19 days following tumor inoculation.
Glucose tolerance test. D-Glucose (2 g/kg body weight) was injected i.p. following a 6 h fast from 7:00 AM. Blood glucose levels before (0 minutes), 20 minutes, 40 minutes, 60 minutes and 90 minutes following glucose injection were measured using a glucometer (Bayer Contour, Switzerland). For measurements of plasma insulin concentration, blood was collected from the tail vein at time points 0 and 20 minutes. Plasma insulin was analyzed by ELISA in duplicates (Mouse Ultrasensitive Insulin ELISA, #80-INSTRU-E10, ALPCO Diagnostics, USA).
Body composition analysis.
Fat mass and lean body mass were determined by quantitative magnetic resonance imaging (EchoMRI-4in1TM, Echo Medical System LLC, USA) 0-2 days before termination. Quantitative magnetic resonance imaging of the tumor itself disclose the tumor as 5% "fat mass" and 95% as "lean body mass" (unpublished observations), and therefore 5% and 95% of the dissected tumor mass was subtracted from the fat mass and lean body mass, respectively. were performed immediately prior to insulin or saline injection and either after 5 and 10 minutes, or after 3, 6, 9, and 12 minutes as indicated in the figures. After 10 or 12 minutes, mice were humanely euthanized by cervical dislocation and the tumor, perigonadal WAT, tibialis anterior (TA), and gastrocnemius muscles were excised and quickly frozen in liquid nitrogen and stored at −80°C until processing. Once tissues were removed, blood was collected by punctuation of the heart, centrifuged (13,000 rpm, 5 minutes) and plasma frozen at -80°C. Plasma samples were analyzed for insulin concentration and specific [3H]2DG tracer activity. Plasma insulin was analyzed as described above. Tissue-specific 2DG uptake was analyzed as described (26, 27) .
Calculations of the whole-body glucose uptake index were performed as follows based on the body mass compositions obtained from the MRI scans: y = a*b, where y is 2DG uptake index (µmol/h), a is 2DG uptake rate (µmol/g/h), b is either tumor, fat, or 0.5*lean mass (g). Half of the lean mass was estimated to be muscle mass based on the study of Rolfe and Brown (28) . It was an assumption that all fat depots on average displayed glucose uptake similar to our measured WAT depot. minutes was used where the first 2 minutes was to ensure systemic steady-state conditions before three consecutive MVP recordings were performed. Data were exported to quantification software (QLab, Philips, Andover, MA, USA) for analysis. Regions of interest were drawn clear of connective tissue and large vessels and copied into each file to ensure that regions were identical for each recording. Calculations were made in accordance with Wei et al. (30) . In short, acoustic intensity (AI) versus time curves were fitted to the exponential function:
where t is time (seconds), Bt is the time used for background subtraction, y is the acoustic intensity at any given t, A is the plateau AI defined as MVP, and β is the flow rate constant (liters·s-1) that determines the rate of rising AI.
Basal and insulin-stimulated hepatic glucose production. Mice (control, n=5, or large (tumor size > 800 mm 3 ) tumor-bearing mice, n=6) were clamped in randomized order after a 4 h fasting period from 10:00 AM. Mice were anesthetized with an i.p. injection of 11 μ l/g body weight of Fentanyl 3H]-glucose (0.83 μ l/minute, 1.2 μ Ci/h). Blood glucose was clamped at 6 mmol/l and maintained by a variable infusion of 20% glucose solution. Blood was sampled from the tail at -10, 0, 105, and 120 minutes for determination of plasma glucose, plasma 3H activity by scintillation counting, and thereby the plasma specific activity. Basal and insulin-stimulated HGP were calculated based on the equation described (31) . At 120 minutes, blood for plasma insulin concentration was also obtained from the tail. Mice were humanely euthanized by cervical dislocation.
Immunoblotting. Mouse muscles was pulverized in liquid nitrogen and homogenized 2 × 0.5 minutes at 30 Hz using a TissueLyser II bead mill (Qiagen, USA) in ice-cold homogenization buffer, pH 7.5 (10% glycerol, 1% NP-40, 20 mM sodium pyrophosphate, 150 mM NaCl, 50 mM HEPES (pH 7.5), 20 mM β -glycerophosphate, 10 mM NaF, 2 mM phenylmethylsulfonyl fluoride (PMSF), 1 mM EDTA (pH 8.0), 1 mM EGTA (pH 8.0), 2 mM Na 3 VO 4 , 10 μ g/ml leupeptin, 10 μ g/ml aprotinin, 3 mM benzamidine). After rotation end-over-end for 30 min at 4°C, supernatants from muscle tissue were collected by centrifugation (10,000 rpm) for 20 minutes at 4°C. Lysate protein concentrations were measured using the bicinchoninic acid method with bovine serum albumin (BSA) as a standard (Pierce). Total proteins and phosphorylation levels of relevant proteins were determined by standard immunoblotting techniques loading equal amounts of protein with a standard curve included for all proteins to ensure quantifications within the linear range.
Polyvinylidene difluoride membranes (Immobilon Transfer Membrane; Millipore) were blocked in Tris-buffered saline (TBS)-Tween 20 containing 2% milk for 10-20 minutes at room temperature.
Membranes were incubated with primary antibodies (Table 1 ) overnight at 4°C, followed by incubation with HRP-conjugated secondary antibody for 45 minutes at room temperature.
Coomassie brilliant blue staining was used as a loading control (32) . Bands were visualized using the Bio-Rad ChemiDoc MP Imaging System and enhanced chemiluminescence (ECL+; Amersham Biosciences). Bands were quantified using Bio-Rad's Image Lab software 6.0.1. 
Results

LLC caused adipose tissue wasting and increased spleen weight, indicative of mild cachexia and inflammation.
Lewis lung carcinoma tumor-bearing (LLC) day 15 mice had an average tumor volume of 530 mm 3 ± 285 mm 3 . LLC day 21-27 mice had an average tumor volume of 1345 mm 3 ± 946 mm 3 (Fig. 1A) . 
LLC tumor-bearing mice displayed insulin resistance
We next investigated the effect of cancer on whole-body insulin action by retro-orbitally injecting a submaximal dose of insulin (unpublished data and (33)) and analyzing blood glucose in control and LLC tumor-bearing mice. The experiment overview is shown in Fig. 2A . In contrast to control mice, insulin did not lower blood glucose in LLC day 15 and LLC day 21-27 tumor-bearing mice 5 minutes following injection ( Fig. 2B ). Furthermore, the blood-glucose-lowering effect of insulin was markedly reduced (by 2-2.5 mM) at 10 minutes in LLC tumor-bearing mice compared to control mice ( Fig. 2B) . Accordingly, the area over the curve (AOC) was 60-80% lower in tumorbearing mice ( Fig. 2B ), suggesting that LLC causes insulin resistance in mice.
Given the reduced whole-body insulin action, we measured glucose uptake in skeletal muscle and WAT, tissues that account for the majority of glucose utilization involved in whole-body glycemic control (34, 35) . In gastrocnemius muscle, insulin-stimulated glucose uptake was reduced in LLC day 15 tumor-bearing mice (-23%, Fig. 2C ) and day 21-27 tumor-bearing mice (-28%, Fig. 2C ) compared with control mice. Likewise, in TA muscle, insulin-stimulated glucose uptake was reduced in LLC day 21-27 tumor-bearing mice (-32%, Fig. 2D ), but surprisingly, increased in LLC day 15 tumor-bearing mice (+45%, Fig. 2D ). In perigonadal WAT, insulin-stimulated glucose uptake tended (P=0.0784) to be decreased by LLC at day 21-27 (-37%, Fig. 2E ), while being increased in LLC at day 15 (+48%, Fig. 2E ). We did not detect changes in glucose uptake ( Fig. 2C -E) or blood glucose ( Fig. S1 ) among saline-treated mice.
Insulin-stimulated glucose uptake in skeletal muscle and white adipose tissue negatively correlated with tumor size.
As tissue-specific insulin resistance was more pronounced at day 21-27 where the tumors were larger compared with day 15, we next investigated whether insulin resistance was related to the tumor size. Thus, we re-divided our current data set into small vs large tumors (cut off 800 mm 3 ) across the LLC day 15 and LLC day 21-27 groups. In mice with large tumors (LLC-L), the bloodglucose-lowering effect of insulin was almost abrogated (Fig. 2F ). However, in mice with small tumors (LLC-S), the blood glucose-lowering effect of insulin was only modestly reduced ( Fig. 2F ).
Accordingly, AOC was 96% reduced in mice with large tumors and tended (P=0.051) to be 47% decreased in mice with small tumors (Fig. 2F ).
In LLC-S tumor-bearing mice, insulin-stimulated glucose uptake tended (P=0.051) to be 19% decreased in gastrocnemius ( Fig. 2G ), increased in TA (+35%, Fig. 2H ), while unaltered in WAT In addition, a negative correlation between tumor size and insulin-stimulated glucose uptake was observed in both skeletal muscle and WAT (Fig. 2J ). These findings show that cancer can significantly reduce insulin-stimulated glucose uptake in skeletal muscle and WAT in a tumor sizedependent manner.
Previous studies have reported that tumors take up glucose at high rates to support tumor growth, migration, and invasion (36, 37) . However, to the best of our knowledge, no study has to date compared glucose uptake into muscle and tumor in the same mouse. We, therefore, analyzed tumor glucose uptake and found that tumor glucose uptake per gram tumor mass was 5.9-and 1.7-fold higher in LLC-S and LLC-L, respectively compared with average basal muscle glucose uptake ( Fig.   2K , P<0.05). Similar results were obtained in the insulin-stimulated state, where the average muscle glucose uptake was 40% that of glucose uptake in tumors of LLC-S tumor-bearing mice (p< 0.01).
Insulin-stimulated glucose uptake was similar in the tumor and muscle of LLC-L tumor-bearing mice ( Fig. 2K ). Those findings suggest that the tumor significantly competes with skeletal muscle for glucose. In order to understand how much the tumor contributed to whole-body glucose disposal during the 10 minutes of stimulations, we produced an index of whole-body glucose disposal in fat, skeletal muscle, and the tumor. It showed that in cancer, a substantial part of the available glucose is directed from muscle and fat into the tumor (Fig. 2L ).
Reduced skeletal muscle glucose uptake in tumor-bearing mice was not due to impaired AKT signaling
We next focused on skeletal muscle, which accounts for the majority of insulin-stimulated glucose disposal (35) , and investigated canonical muscle insulin signaling to elucidate the molecular mechanisms underlying LLC-induced muscle insulin resistance. We focused our investigation on mice with tumor size of more than 800 mm 3 (average tumor volume 1755 ± 763 mm 3 ) as insulin resistance was pronounced in this group. Even though insulin-stimulated muscle glucose uptake was markedly reduced in LLC-L tumor-bearing mice, the phosphorylation of AKT Ser473 (+65%, Fig.   3A ), AKT Thr308 (+86%) (Fig. 3B) , and TBC1D4 Thr642 (+18%, Fig. 3C ) were upregulated (representative phospho-blots are shown in Fig. 3D ). Protein expression of AKT2 (Fig. 3E ), TBC1D4 ( Fig. 3F ), glucose transporter 4 (GLUT4) (Fig. 3G) , and Hexokinase II (Fig. 3H) remained unaltered in tumor-bearing mice (representative blots of total proteins are shown in Fig.   3I ), although we did detect a tendency (p=0.0529) to increased protein expression for TBC1D4 in tumor-bearing mice.
These findings suggest that reduced insulin-stimulated muscle glucose uptake in tumor-bearing mice is not due to decreased myocellular canonical insulin signaling, on the contrary, we observed augmented phosphorylation of both AKT and TBC1D4.
Tumor-bearing mice displayed abrogated muscle microvascular perfusion in response to insulin
Muscle microvascular perfusion (MVP) is essential for insulin to fully stimulate glucose uptake in muscle, however, it is unknown whether cancer influences muscle MVP. Thus, we determined muscle MVP in mice with tumor size more than 800 mm 3 (LLC-L, averaged tumor volume 1283 ± 207 mm 3 ). In control mice, insulin increased muscle MVP (+70%; Fig. 4A and B) in accordance with previous studies (38, 39) . Remarkably, this increase was completely abrogated in LLC-L tumor-bearing mice ( Fig. 4C and D) , showing that cancer negatively affects insulin-stimulated muscle microvascular perfusion, which could contribute to muscle insulin resistance.
Tumor-bearing mice exhibit increased basal hepatic glucose production
Increased hepatic glucose production (HGP) is another hallmark of insulin resistance. Therefore, we measured basal and insulin-stimulated HGP in mice with tumor size of more than 800 mm 3 (LLC-L, averaged tumor volume 3916 ± 2196 mm 3 ). Following 120 minutes of continuous insulin infusion (7.5 μ U/kg/minute), blood glucose in both control and LLC-L tumor-bearing mice was maintained at a steady level of 6 mM (Fig. 5A ). Steady-state glucose infusion rate (GIR) during the clamp was similar between control and tumor-bearing mice (Fig. 5B ). This is in contrast to our findings during the 10 minutes insulin stimulation where tumor-bearing mice displayed reduced insulin response.
This discrepancy might reflect the fact that the tumor takes up a large proportion of the glucose in the tumor-bearing mice as indicated by Fig. 2K and L. Over time that could masks smaller reductions in muscle and adipose tissue glucose uptake. It could also reflect the longer stimulation time (the last 30 minutes of the clamp used to calculate GIR), or that the insulin dose used to estimate GIR was higher compared with the r.o. stimulation.
Interestingly, basal HGP of LLC-L tumor-bearing mice was 45%increased compared to control mice (Fig. 5C ). In addition, basal HGP positively correlated with tumor volume ( Fig. 5D) . At a supra-physiological insulin dose, insulin suppressed HGP similarly in LLC-L tumor-bearing and control mice (Fig. 5C ). Nevertheless, within the tumor-bearing group, the inhibitory effect of insulin on HGP was negatively correlated with tumor volume (Fig. 5E ), although this should be interpreted cautiously, given the low number of mice. Collectively, these findings show that cancer increases basal HGP, but does not affect insulin-stimulated GIR or insulin-suppressed HGP at supra-physiological insulin levels.
Inhibition of fatty acid oxidation or lipolysis partially restored LLC-induced insulin resistance
Augmented fatty acid metabolism, a hallmark of many insulin resistance conditions (18, 40, 41) , has been reported in human (42) and murine (21, 22) cancer models. Therefore, we tested the hypothesis that cancer might reduce insulin action via its effect on fatty acid metabolism in LLC tumor-bearing mice (averaged tumor volume 645 ± 386 mm 3 ). In agreement with previous reports in cancer patients (15) (16) (17) and mouse cancer models (21, 22) , we observed increased plasma triacylglycerol (+23%, Fig. 6A ), FFA (+125%, Fig. 6B ) and glycerol (+40%, Fig. 6C ) concentrations in LLC tumor-bearing compared to control mice. Daily administration of a CPT1 inhibitor, etomoxir, showed that inhibition of whole-body fatty acid oxidation restored blood fatty acid concentrations to levels of control mice ( Fig. 6A-C) . It suggests that inhibition of fatty acid oxidation at least partially corrects abnormal lipid metabolism induced by cancer in mice as measured by plasma triacylglycerol, free fatty acids, and glycerol. Next, we treated mice with insulin to determine insulin's blood-glucose-lowering effect. In control mice, insulin lowered blood glucose by 2 mM and 4 mM following 5 and 10 minutes of stimulation, respectively (Fig. 6D ). In agreement with our previous observations in the present study, insulin action in LLC tumor-bearing mice was reduced ( Fig. 6D ). Remarkably, inhibited fatty acid oxidation, obtained by etomoxir administration, rescued insulin action in LLC tumor-bearing mice evidenced by restored blood glucose levels ( Fig. 6D) and 2.5-fold increase of AOC (Fig. 6E ). We also analyzed plasma insulin concentration 10 minutes following the r.o. insulin injection, as a marker of insulin clearance. Interestingly, LLC tumorbearing mice showed increased plasma insulin (+237%) (Fig. 6F) , an indication of reduced insulin clearance, which is also observed in diet-induced insulin-resistant mice (43, 44) . Etomoxir administration normalized plasma insulin levels in LLC tumor-bearing mice (Fig. 6F ). In order to evaluate glycemic regulation, we undertook a glucose tolerance test and found that tumor-bearing mice were glucose intolerant ( Fig. 6G ). Glucose intolerance was not rescued by etomoxir ( Fig. 6G and H), despite the improvements in circulating fatty acid levels and insulin action. The glucose challenge increased plasma insulin levels 100-150% similarly in all groups (Fig. S2A ). Tumor volume was not affected by etomoxir treatment (Fig. S2B) . Spleen weight increased similarly in tumor-bearing mice with or without etomoxir treatment (Fig. S2C ).
We next inhibited adipose tissue lipolysis by a potent inhibitor, nicotinic acid. In contrast to etomoxir, nicotinic acid restored glucose intolerance in LLC-tumor-bearing mice (Fig. 7A+B ). The glucose challenge increased plasma insulin levels similarly (100-150%) in all groups (Fig. 7C ),
suggesting that altered insulin sensitivity rather than insulin levels caused the improvement in glucose tolerance by nicotinic acid. However, the blood glucose response to r.o. injected insulin was not improved by nicotinic acid (Fig. S3A+B) . Tumor size and tumor growth rate were not affected by nicotinic acid treatment (Fig. S3C) . Spleen weight increased similarly in tumor-bearing mice with or without nicotinic acid treatment ( Fig. S3D ), suggesting that nicotinic acid did not prevent cancer-induced inflammation. Taken together, these findings demonstrate that altered fatty acid metabolism could be an underlying mechanism for LLC-induced insulin resistance.
Discussion
We show that cancer can result in marked perturbations on at least six metabolically essential functions; i) insulin's blood-glucose-lowering effect, ii) glucose tolerance, iii) skeletal muscle and white adipose tissue insulin-stimulated glucose uptake, iv) intramyocellular insulin signaling, v) muscle microvascular perfusion, and vi) basal hepatic glucose production in mice. Additionally, we
show that the mechanism causing cancer-induced insulin resistance may relate to increased fatty acid oxidation or increased fatty acid availability.
A major finding in the current study was the significantly impaired insulin-stimulated glucose uptake in both skeletal muscle and white adipose tissue in LLC tumor-bearing mice. These findings suggest that skeletal muscle and adipose tissue are major players in dysregulated glucose metabolism often observed in human cancers and murine cancer models (45) (46) (47) . Furthermore, whole-body insulin resistance was observed prior to the loss of body mass, which supports the hypothesis that insulin resistance could cause cancer-associated cachexia, rather than vice versa (3) (4) (5) . Tumor size seemed to be a key factor in peripheral insulin resistance, as we observed the skeletal muscle and white adipose tissue glucose uptake to be negatively correlated with tumor size.
Interestingly, the decreased insulin-stimulated glucose uptake in mice with large tumors was not due to diminished proximal insulin signaling in muscle. On the contrary, insulin-stimulated AKT/TBC1D4 signaling was upregulated in skeletal muscle of tumor-bearing mice. This is surprising, given that tumor-bearing mice displayed increased whole-body inflammation as indicated by increased spleen volume. Inflammation would be expected to reduce insulin signaling in muscle (48) . Tumorkines, such as VEGF and HIF-1, are reported to be upregulated in the LLC model of cancer (49, 50) and those tumorkines have been found to increase PI3K/AKT signaling in cancer cells (37, 51) . Although circulating tumorkines were not analyzed in our study, we speculate that PI3K/AKT-activating tumorkines could cause increased insulin signaling in muscle. Another explanation for increased insulin-stimulated AKT/TBC1D4 signaling could be the observation that tumor-bearing mice had reduced insulin clearance, thus having slightly higher plasma insulin when the tissues were harvested. The causes of upregulated muscle insulin signaling in cancer warrants further investigation but increased insulin signaling in muscles with reduced insulin-stimulated glucose uptake has been reported in other models (52) . Nevertheless, the mechanisms by which cancer causes insulin resistance seems to be different from the mechanisms causing insulin resistance in for example obesity and type 2 diabetes, where muscle AKT and TBC1D4 signaling is either unaffected (53, 54) or reduced (55) (56) (57) .
Another major finding of the present investigation was that insulin-stimulated muscle microvascular perfusion was abrogated in tumor-bearing mice. To our knowledge, these data are the first to show that dysregulated muscle microvascular perfusion is involved in a common model of cancer and cachexia. Insulin-stimulated microvascular perfusion in muscle is a critical facet in glucose uptake regulation (8, 39, (58) (59) (60) . In agreement, genetic or pharmacological inhibition of microvascular perfusion impaired insulin-stimulated muscle glucose uptake by 40% in otherwise healthy mice (38) . In addition, insulin-stimulated microvascular perfusion is reduced in different insulin-resistant conditions, including obesity and type diabetes (11, 12) . In cancer, accelerated adipose tissue lipolysis leading to higher circulating fatty acid levels has been observed in mice and humans (21) .
This might cause the impaired muscle microvascular perfusion, as experimentally elevated circulating fatty acids reduced insulin-stimulated muscle microvascular perfusion by 40% (61, 62) without causing impairments in intracellular insulin signaling in humans (19) . Our findings show that decreased microvascular perfusion could contribute to cancer-induced impaired muscle glucose uptake in response to insulin.
In our study, a reduction in skeletal muscle and white adipose tissue glucose uptake likely contributed to the attenuated blood-glucose-lowering effect of insulin in tumor-bearing mice. On the other hand, Lang et al (63) have previously reported that insulin resistance in tumor-bearing rats was due to an impaired ability of insulin to suppress hepatic glucose production, although that study did not analyze muscle and adipose tissue glucose uptake. In the present study, insulin's inhibitory effect on hepatic glucose production was not impaired while basal hepatic glucose production was 45% increased. Increased basal hepatic glucose production has also been reported in patients with cancer (64) . Based on our findings, future work should investigate the mechanism by which cancer, or the metabolic imprint of cancer, influences basal hepatic glucose production.
Elevation of fatty acids is often associated with insulin resistance (18) (19) (20) and increased plasma fatty acid concentrations are reported in cancers (21, 22, 46, 65) . For example, the release of fatty acids and glycerol from WAT explants was 30-40% increased in LLC or B16 tumor-bearing mice (21) . Increased circulating fatty acids have been shown to induce insulin resistance (66) . Indeed, we found that whole-body insulin action was restored by blocking fatty acid oxidation via etomoxir administration in tumor-bearing mice. Furthermore, lipolysis inhibition via nicotinic acid administration rescued glucose intolerance in tumor-bearing mice. Interestingly, etomoxir normalized plasma triacylglycerol, fatty acids, and glycerol concentrations in tumor-bearing mice, which could benefit insulin action. The fatty-acid-lowering effect of etomoxir is somewhat surprising, as fatty acid oxidation blockade would be expected to increase circulating levels of fatty acids, as has also been reported in non-tumor-bearing rodents treated with etomoxir at doses higher (67, 68) than in the present investigation. However, etomoxir inhibits lipolysis in adipocytes and can increase re-esterificationof fatty acids to triacylglycerol in the liver, thereby diminishing the release of fatty acids from the adipose tissue and triacylglycerol from the liver (69). In the cancer condition with accelerated lipolysis (15, 17) , it is possible that etomoxir's effect on triacylglycerol metabolism seen in liver and lipolysis overrules the contrary effect of etomoxir on reduced fatty acid oxidation.
Etomoxir has also been reported to reduce inflammation (70, 71) , which could also contribute to the amelioration of cancer-induced insulin resistance. However, spleen weight increased similarly in tumor-bearing mice with or without etomoxir treatment, suggesting that etomoxir did not prevent cancer-induced inflammation. Indeed, our results indicate that the impact of cancer on lipid metabolism exerts a critical impact on the pathology of cancer-induced insulin resistance. However, the mechanism by which etomoxir and nicotinic acid restored insulin action was not determined by our study and should be the topic for future investigations.
Based on the present investigation, we hypothesize a model where the tumor secretes tumorkines that increase fatty acid metabolism, which in turn leads to peripheral insulin resistance. Redirecting glucose from skeletal muscle and adipose tissue, likely benefits the tumor's energy demand to support tumor growth, migration, and invasion (36) . The clinical relevance of this is suggested, as cancer patients with type 2 diabetes have increased mortality rates (2).
In conclusion, cancer impaired the blood-glucose-lowering effect of insulin, caused glucose intolerance, and reduced glucose uptake in muscle and white adipose tissue. Furthermore, tumorbearing mice displayed increased basal hepatic glucose production. Cancer-associated insulin resistance was not due to impaired proximal muscle insulin signaling, but was associated with a complete abrogation of insulin-stimulated muscle microvascular perfusion. Finally, we identify fatty acid metabolism as a player in cancer-associated insulin resistance, providing potential therapeutic targets for cancer-induced insulin resistance. These findings suggest that insulin resistance is likely of key importance in the therapy of cancer and cachexia. 
